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ABSTRACT 19 
Purpose of the review: The healthy protective effects of coffee against several metabolic diseases 20 
and some types of cancer. In this short review, the possible preventive and/or therapeutic actions of 21 
coffee on liver function is focused. 22 
Recent findings: The protective mechanisms of coffee are various and due to several components 23 
with anti-inflammatory and antioxidant properties besides caffeine.  24 
As a matter of the fact, polyphenols in decaffeinated coffee have a similar effect on liver fibrosis 25 
and on serum levels of liver enzymes as those in caffeinated coffee. 26 
Furthermore, diterpenes may exert a detoxifying action and antioxidant activity, with benefits on 27 
liver fibrosis, cirrhosis and cancer. 28 
Summary A regular coffee consumption may have preventive healthy effects, especially if 29 
consumed without added sugars. Certainly, coffee consumption should not be prohibited in 30 
individuals with chronic inflammatory liver diseases, including hepatocellular carcinoma. 31 
 32 
Keywords: coffee, caffeine, liver diseases, cancer  33 
 34 
  35 
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INTRODUCTION 36 
Recent literature offers a series of comprehensive reviews on the health effects of coffee in 37 
beverage form as evaluated for the presence or absence of caffeine (caffeinated or decaffeinated, 38 
respectively), other specific minor chemical components, the type of seed utilized (Arabica versus 39 
Robusta variety), and the method of preparation (instant, espresso, boiled, filtered, etc). [1-3]  40 
The overall impression is that coffee has a healthy protective action against neurodegenerative, 41 
liver, cardiovascular, and metabolic diseases and some types of cancer when it is consumed, in the 42 
absence of specific contraindications or intolerance and according to individual sensibility, at the 43 
reasonable dose of 1-3 (2-4) cups of caffeinated coffee per day, corresponding to 100-400 mg 44 
caffeine per day. [1,2]  45 
In this short review, we will focus on the possible preventive and/or therapeutic actions of caffeine 46 
(but also of coffee in beverage form as a whole) on liver function in chronic inflammatory liver 47 
diseases such as steatosis, steatohepatitis, cirrhosis, and cancer and on its role in limiting 48 
progression of these types of diseases. 49 
WHAT IS COFFEE? 50 
Coffee is the most frequently consumed beverage worldwide; it is prepared from the seeds of a 51 
plant, of the family Rubiaceae and genus Coffea and includes a number of different species. Coffee 52 
is mainly produced from the coffee seeds of the Arabica and Robusta varieties. Besides caffeine (an 53 
alkaloid of the methylxanthine family), coffee contains many other specific compounds, 54 
representing a rich source of phenols, polyphenols, flavonoids, non-flavonoids, melanoidins, etc., 55 
most of which have anti-inflammatory and antioxidant properties. [4] Chlorogenic acids (CGAs) in 56 
particular belong to the conjugated hydroxycinnamate family of non-flavonoid phenols; CGAs are 57 
the most abundant antioxidant in coffee. A percentage of CGAs and flavonoids is degraded by 58 
roasting temperatures of 230 °C, but alternative antioxidant compounds are formed, thus 59 
maintaining an overall strong active antioxidant property. [5] For these elementary reasons, coffee 60 
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is completely different from other diffusely marketed, non-natural, caffeine-rich soft drinks (with or 61 
without added sugars). 62 
 63 
CHRONIC INFLAMMATORY LIVER DISEASES 64 
Liver steatosis (either non-alcoholic fatty liver disease (NAFLD), which is often associated with 65 
metabolic syndrome, or alcoholic fatty liver disease (AFLD)) pathogenesis is metabolically 66 
characterized by alteration of hepatic synthesis and of metabolism of fatty acids (FAs) and 67 
triglycerides (TGs). Marventano et al. in particular support the concept that NAFLD and metabolic 68 
syndrome are interrelated, as they share common pathogenic determinants such as insulin resistance 69 
and oxidative stress. [3,6,7] In their review the authors discuss a study by Malloy et al. showing an 70 
inverse correlation of prevalence and severity of biopsy-proven fibrosis of NAFLD and coffee 71 
caffeine consumption but not of prevalence and severity of fibrosis and total caffeine intake. [8-9]  72 
The presence of these metabolic alterations in predisposed individuals or in others with related 73 
diseases such as type 2 diabetes predisposes the liver to the aggressive action of inflammatory 74 
cytokines with increased oxidative stress, leading to steatohepatitis and cirrhosis or even to 75 
hepatocellular carcinoma, the most frequent type of liver cancer. [10, 11] Reactive oxygen species 76 
(ROS) generation in fact stimulates TNF-alpha production, and TNF-alpha action may impair 77 
cellular function, potentially resulting in hepatic fibrogenesis and necrosis through increased nitric 78 
oxide production. In conclusion, oxidative stress seems to be the most important factor in different 79 
pathways leading to fibrogenesis and consequently to NASH. 80 
COFFEE PROTECTIVE EFFECTS 81 
a) Suggested mechanisms 82 
The protective mechanisms of coffee are various and due to several components of coffee besides 83 
caffeine. Coffee appears to exert this protective action independently of the type of noxa (e.g. 84 
alcohol, virus, diabetes, and metabolic syndrome). [11]   Caffeine exerts its protective effects on 85 
liver function by beta oxidative stimulation of lipolysis, lipogenesis and oxidative stress 86 
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suppression. In rats, liver steatosis, experimentally induced by a high fat diet (HFD), is 87 
characterized by increased serum bilirubin, ALT, AST, and Hyper TG. Increased oxidative stress is 88 
attenuated by caffeine due to reduced hepatic fatty acid synthesis and to acetyl CoA carboxylase 89 
activity associated with increased activity of peroxisome proliferation-activated receptor alpha 90 
(PPAR-alpha) and of carnitine-palmitoyl-transferase 1 (CPT1). [12]    During fatty acid synthesis, 91 
concurrent caffeine administration reduces lipogenesis and stimulates lipid beta-oxidation after 92 
consumption of a high-fat diet. Furthermore, PPAR-alpha stimulation activates the lipoprotein 93 
lipase, which reduces fat accumulation but also has anti-inflammatory and antioxidative effects. 94 
[13]   These experimental findings support a previous epidemiological observation carried out on a 95 
multi-ethnic US population of 125,580 liver disease-free individuals, showing the protective action 96 
of regular coffee against liver cirrhosis, especially alcohol-induced liver cirrhosis. [3]  Another 97 
beneficial effect of caffeine is specifically that it is anti-fibrotic and prevents hepatic stellate cell 98 
(HSC) adhesion and activation. In fact, after their activation due to hepatocyte damage, HSCs 99 
differentiate into myofibroblast-like cells and secrete extracellular matrix leading to hepatic fibrosis. 100 
[14]    In alcoholic liver fibrosis (ALF), ethanol oxidation produces a highly reactive acetaldehyde 101 
compound, which stimulates type 1 collagen, which activates hepatic stellate cells. Caffeine may 102 
inhibit this process by inhibiting the cAMP/PKA/CREB protein expression signal pathway through 103 
adenosine A2A receptors in HSCs. The beneficial effects of other non-caffeine chemical 104 
components of coffee beans come indirectly from the observation that decaffeinated coffee exerts 105 
similar effects, although to a lesser degree, to caffeinated coffee. Diterpenes (i.e., cafestol, kahweol) 106 
may have an antioxidant action through stimulation of glutathione-5-transferases (GSTs) and 107 
nuclear factor erythroid 2-related factor 2 (Nrf-2). [1]   Furthermore, melanoidins, brown-coloured 108 
compounds present in coffee, confer significant protection against oxidative noxae in human 109 
HepG2 cells by reducing TNF-alpha and tissue transglutaminase and by transforming growth factor 110 
beta expression in the liver. [3, 15, 16]    Other, still not identified, coffee components, besides 111 
caffeine and diterpenes, may have a protective action on progression to hepatic liver cirrhosis by 112 
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upregulating glucuronidation processes. Finally, individual genotype and gut microbiota may affect 113 
the bioavailability and selection of the type of absorbed metabolites.[17]    114 
b) Some experimental, epidemiological and clinical evidence 115 
Poole et al. in their recent meta-analysis confirm previous findings and add that in habitual coffee 116 
consumers, there is also present a significant dose-response relation for coffee consumption and low 117 
risk of several types of cancer, including prostate, endometrial, melanoma and liver cancers; in 118 
addition, a low risk of NAFLD, liver fibrosis and cirrhosis was reported. [1]   A significantly lower 119 
risk of gallstone disease has also been observed in coffee consumers than in non-consumers. [13] A 120 
part of the direct positive effect of caffeine on liver fibrosis is due to polyphenols, as indirectly 121 
shown by the observation that polyphenols in decaffeinated coffee have a similar, but to a lesser 122 
degree, effect on serum levels of liver enzymes as those in caffeinated coffee. [18]   Furthermore, 123 
Vitaglione et al. observed, in an experimental model of rats fed a high-fat diet, that coffee 124 
polyphenols decrease oxidative stress, insulin resistance and liver fibrosis. [15]  Diterpenes may 125 
exert their preventive action against liver fibrosis, cirrhosis and liver cancer through a detoxifying 126 
effect in which intracellular antioxidant activity is stimulated. [4]   127 
CONCLUSIONS 128 
Coffee is a natural, complex drink with a consumer base that is widely found throughout the world 129 
and is not confused with other still popular caffeine-rich soft drinks. Regular coffee consumption 130 
has, generally speaking, a beneficial health effect, although its consumption has some 131 
contraindications (increased gastric acid secretion, anxiety, insomnia, palpitation) and some 132 
individuals may be intolerant, as may happen for many natural substances. Coffee, as a whole and 133 
through many of its specific components, appears to be beneficial more as a preventive agent than 134 
as a therapeutic agent; consequently, data are limited to suggest its use as a therapeutic agent in 135 
liver fibrosis, cirrhosis, and hepato-cellular carcinoma. However, coffee is not contraindicated in 136 
these clinical conditions, particularly if assumed without added sugars. Although experimental data 137 
confirm these effects, we cannot exclude, as already suggested, that coffee is also a surrogate 138 
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marker of social wellness, high income and education, which positively and directly affect human 139 
health. Other factors biasing the results may include the possible relation between the method of 140 
preparation and consumption and the degree of effectiveness. In fact, it is difficult to determine if 141 
seed variety, brand, and brewing method may influence coffee’s efficacy in protecting liver 142 
function and in performing the described beneficial effects on other organs and processes. In our 143 
opinion, regular consumption, 2 – 4 cups per day, without added sugars, particularly sucrose and 144 
fructose, is important. 145 
A positive, conclusive suggestion may be that coffee consumption is not prohibited in individuals 146 
with chronic inflammatory liver diseases, including hepatocellular carcinoma. 147 
 148 
KEY POINTS 149 
Coffee exerts detoxifying and antioxidant effects with benefits on liver fibrosis, cirrhosis and 150 
cancer. 151 
Coffee healthy protective effects have been described also against several metabolic diseases and 152 
some types of cancer. 153 
Besides caffeine, other coffee components (polyphenols, diterpenes) have anti-inflammatory and 154 
antioxidant properties. 155 
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